Genotype-Guided Antiplatelet Therapy Versus Standard Therapy for Patients with Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis
CONCLUSION: Genotype-guided antiplatelet treatment could reduce the risk of MACEs without increasing the risk of bleeding events as compared with the standard treatment in patients with CAD or those undergoing PCI. In addition, Genotype-guided antiplatelet treatment might benefit Chinese population or patients with ACS.PMID:34995471 | DOI:10.18433/jpps32140
Source: J Pharm Pharm Sci - Category: Drugs & Pharmacology Authors: Borui Tang Xin Wang Xinrui Wang Lihong Liu Zhuo Ma Source Type: research
More News: Angioplasty | Bleeding | Cardiology | Cardiovascular | China Health | Coronary Angioplasty | Databases & Libraries | Drugs & Pharmacology | Heart | Heart Attack | Percutaneous Coronary Intervention | Science | Statistics | Stroke | Study | Thrombosis